Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Defining the signatures of peripheral T-cell lymphoma, with a targeted 20-markers gene expression profiling assay (RT-MLPA).

Drieux F, Ruminy P, Abdel-Sater A, Lemonnier F, Viailly PJ, Fataccioli V, Machand V, Bisig B, Letourneau A, Parrens M, Bossard C, Bruneau J, Dobay P, Veresezan L, Dupuy A, Pujals A, Robe C, Sako N, Copie-Bergman C, Delfau-Larue MH, Picquenot JM, Tilly H, Delarue R, Jardin F, de Leval L, Gaulard P; TENOMIC.

Haematologica. 2019 Sep 5. pii: haematol.2019.226647. doi: 10.3324/haematol.2019.226647. [Epub ahead of print]

2.

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.

Ogasawara K, Newhall K, Maxwell SE, Dell'Aringa J, Komashko V, Kilavuz N, Delarue R, Czuczman M, Sternas L, Rose S, Beach CL, Novick S, Zhou S, Palmisano M, Li Y.

Clin Pharmacokinet. 2019 Jul 22. doi: 10.1007/s40262-019-00804-x. [Epub ahead of print]

PMID:
31332669
3.

Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma.

Crickx E, Poullot E, Moulis G, Goulabchand R, Fieschi C, Galicier L, Meignin V, Coppo P, Delarue R, Casasnovas O, Roos-Weil D, de Leval L, Parrens M, Michel M, Dupuis J, Le Bras F, Fataccioli V, Martin-Garcia N, Godeau B, Haïoun C, Gaulard P, Mahévas M.

Eur J Haematol. 2019 Jul;103(1):35-42. doi: 10.1111/ejh.13239. Epub 2019 May 30.

PMID:
30985955
4.

Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.

Mounier N, Anthony S, Busson R, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais-Guillaumot F, Damaj G, Nerich V, Jais JP, Laborde L, Salles G, Henry-Amar M.

Cancer. 2019 Mar 22. doi: 10.1002/cncr.32040. [Epub ahead of print]

PMID:
30901086
5.

[Management of microcytic anemia].

Aoun C, Delarue R.

Rev Prat. 2018 Sep;68(7):e288. French. No abstract available.

PMID:
30869342
6.

[Iron pathology in adults and children].

Aoun C, Delarue R.

Rev Prat. 2018 Sep;68(7):e283-e287. French. No abstract available.

PMID:
30869341
7.

[Monoclonal gammopathies: 10 key messages].

Delarue R.

Rev Prat. 2018 Sep;68(7):803. French. No abstract available.

PMID:
30869337
8.

GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors.

Chiche J, Reverso-Meinietti J, Mouchotte A, Rubio-Patiño C, Mhaidly R, Villa E, Bossowski JP, Proics E, Grima-Reyes M, Paquet A, Fragaki K, Marchetti S, Briere J, Ambrosetti D, Michiels JF, Molina TJ, Copie-Bergman C, Lehmann-Che J, Peyrottes I, Peyrade F, de Kerviler E, Taillan B, Garnier G, Verhoeyen E, Paquis-Flucklinger V, Shintu L, Delwail V, Delpech-Debiais C, Delarue R, Bosly A, Petrella T, Brisou G, Nadel B, Barbry P, Mounier N, Thieblemont C, Ricci JE.

Cell Metab. 2019 Jun 4;29(6):1243-1257.e10. doi: 10.1016/j.cmet.2019.02.002. Epub 2019 Feb 28.

PMID:
30827861
9.

Distal interphalangeal joint arthrodesis with the intramedullary Lync® implant: Prospective study of 22 cases.

Auzias P, Delarue R, Strouk G, Guerre E, Limousin M, Fontaine C, Aumar A.

Hand Surg Rehabil. 2019 Apr;38(2):114-120. doi: 10.1016/j.hansur.2019.01.004. Epub 2019 Jan 30.

PMID:
30708120
10.

Concurrent cerebral aspergillosis and abdominal mucormycosis during ibrutinib therapy for chronic lymphocytic leukaemia.

Pouvaret A, Guery R, Montillet M, Molina TJ, Duréault A, Bougnoux ME, Galliot R, Lanternier F, Delarue R, Lortholary O.

Clin Microbiol Infect. 2019 Jun;25(6):771-773. doi: 10.1016/j.cmi.2019.01.016. Epub 2019 Jan 29. No abstract available.

PMID:
30703527
11.

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M.

Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15.

PMID:
30658935
12.

NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.

Cheminant M, Bruneau J, Malamut G, Sibon D, Guegan N, van Gils T, Cording S, Trinquand A, Verkarre V, Lhermitte L, Brousse N, Jannot AS, Khater S, Frenzel L, Delarue R, Suarez F, Marçais A, Mulder CJ, Macintyre E, Asnafi V, Pouyet L, Bonnafous C, Lhospice F, Molina TJ, Meresse B, Cellier C, Cerf-Bensussan N, Hermine O; CELAC network°.

Gut. 2019 Aug;68(8):1396-1405. doi: 10.1136/gutjnl-2018-317371. Epub 2018 Nov 17.

PMID:
30448772
13.

Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.

Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, Pelletier L, Marçais A, Robe C, Fataccioli V, Haioun C, Hermine O, Gaulard P, Delarue R.

Blood. 2018 Nov 22;132(21):2305-2309. doi: 10.1182/blood-2018-04-840538. Epub 2018 Oct 2. No abstract available.

PMID:
30279227
14.

Multiple Ways to Detect IDH2 Mutations in Angioimmunoblastic T-Cell Lymphoma from Immunohistochemistry to Next-Generation Sequencing.

Dupuy A, Lemonnier F, Fataccioli V, Martin-Garcia N, Robe C, Pelletier R, Poullot E, Moktefi A, Mokhtari K, Rousselet MC, Traverse-Glehen A, Delarue R, Tournilhac O, Delfau-Larue MH, Haioun C, Ortonne N, Copie-Bergman C, de Leval L, Pujals A, Gaulard P.

J Mol Diagn. 2018 Sep;20(5):677-685. doi: 10.1016/j.jmoldx.2018.05.012. Epub 2018 Jul 5.

PMID:
29981867
15.

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

Maurer MJ, Ghesquières H, Link BK, Jais JP, Habermann TM, Thompson CA, Haioun C, Allmer C, Johnston PB, Delarue R, Micallef IN, Peyrade F, Inwards DJ, Ketterer N, Farooq U, Fitoussi O, Macon WR, Molina TJ, Syrbu S, Feldman AL, Slager SL, Weiner GJ, Ansell SM, Cerhan JR, Salles GA, Witzig TE, Tilly H, Nowakowski GS.

J Clin Oncol. 2018 Jun 1;36(16):1603-1610. doi: 10.1200/JCO.2017.76.5198. Epub 2018 Apr 19.

16.

RNA fusions involving CD28 are rare in peripheral T-cell lymphomas and concentrate mainly in those derived from follicular helper T cells.

Vallois D, Dupuy A, Lemonnier F, Allen G, Missiaglia E, Fataccioli V, Ortonne N, Clavert A, Delarue R, Rousselet MC, Fabiani B, Llamas-Gutierrez F, Ogawa S, Thome M, Ko YH, Kataoka K, Gaulard P, de Leval L.

Haematologica. 2018 Aug;103(8):e360-e363. doi: 10.3324/haematol.2017.186767. Epub 2018 Mar 15. No abstract available.

17.

Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.

Cabannes-Hamy A, Peyrade F, Jardin F, Emile JF, Delwail V, Mounier N, Haioun C, Perrot A, Fitoussi O, Lara D, Delarue R, André M, Offner F, Ghesquières H, Pascal L, Soussain C, Lazarovici J, Schiano JM, Gaulard P, Tilly H, Thieblemont C; LYSA; lymphoma study association.

Cancer Med. 2018 Mar;7(3):539-548. doi: 10.1002/cam4.1139. Epub 2018 Feb 23.

18.

Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers.

Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Le Bras F, Willems E, Tchernonog E, Chalopin T, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquières H, Tournilhac O, da Silva MG, Bouabdallah R, Salles G, Bachy E.

Ann Oncol. 2018 Mar 1;29(3):715-723. doi: 10.1093/annonc/mdx787.

PMID:
29253087
19.

[Lymphomas: A therapeutic update].

Wolfromm A, Delarue R.

Rev Med Interne. 2017 Oct;38(10):685-690. doi: 10.1016/j.revmed.2017.07.007. Epub 2017 Sep 28. Review. French.

PMID:
28958786
20.

Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.

Besson C, Lancar R, Prevot S, Algarte-Genin M, Delobel P, Bonnet F, Meyohas MC, Partisani M, Oberic L, Gabarre J, Goujard C, Boue F, Coppo P, Costello R, Hendel-Chavez H, Mekerri N, Dos Santos G, Recher C, Delarue R, Casasnovas RO, Taoufik Y, Mounier N, Costagliola D; ANRS-CO16 LYMPHOVIR Cohort.

AIDS. 2017 Nov 28;31(18):2493-2501. doi: 10.1097/QAD.0000000000001652.

PMID:
28926410
21.

Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study.

Morel A, Brière J, Lamant L, Loschi M, Haioun C, Delarue R, Tournilhac O, Bachy E, Sonet A, Amorim S, Laurent C, Gaulard P, Tilly H, Sibon D.

Eur J Cancer. 2017 Sep;83:146-153. doi: 10.1016/j.ejca.2017.06.026. Epub 2017 Jul 20.

PMID:
28735072
22.

FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.

Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, Tricot S, Gabarre J, Andre M, Fruchart C, Mounier N, Delarue R, Meignan M, Berriolo-Riedinger A, Bardet S, Emile JF, Jais JP, Haioun C, Tilly H, Morschhauser F.

Blood. 2017 Sep 14;130(11):1315-1326. doi: 10.1182/blood-2017-02-766691. Epub 2017 Jul 12.

PMID:
28701367
23.

ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.

Fermé C, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, Lugtenburg PJ, Bouabdallah R, Carde P, Sebban C, Eghbali H, Salles G, van Imhoff GW, Thyss A, Noordijk EM, Reman O, Lybeert MLM, Janvier M, Spina M, Audhuy B, Raemaekers JMM, Delarue R, Anglaret B, de Weerdt O, Marjanovic Z, Tersteeg RJHA, de Jong D, Brière J, Henry-Amar M; European Organisation for Research and Treatment of Cancer Lymphoma Group, and; Groupe d'Étude des Lymphomes de l'Adulte.

Eur J Cancer. 2017 Aug;81:45-55. doi: 10.1016/j.ejca.2017.05.005. Epub 2017 Jun 8.

PMID:
28601705
24.

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.

Petrella T, Copie-Bergman C, Brière J, Delarue R, Jardin F, Ruminy P, Thieblemont C, Figeac M, Canioni D, Feugier P, Fabiani B, Leroy K, Parrens M, André M, Haioun C, Salles GA, Gaulard P, Tilly H, Jais JP, Molina TJ.

Ann Oncol. 2017 May 1;28(5):1042-1049. doi: 10.1093/annonc/mdx022.

PMID:
28327893
25.

Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area.

Gay C, Delarue R, Milpied N, Oberic L, Coiffier B, Boussetta S, Haioun C, Tilly H, Salles G, Lamy T, Lester MA, Houot R.

Blood. 2017 May 18;129(20):2811-2813. doi: 10.1182/blood-2017-02-766147. Epub 2017 Mar 16. No abstract available.

26.

Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.

André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J.

J Clin Oncol. 2017 Jun 1;35(16):1786-1794. doi: 10.1200/JCO.2016.68.6394. Epub 2017 Mar 14.

PMID:
28291393
27.

[Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment].

Anthony S, Hebel P, Garrel A, Oliveri V, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais F, Damaj G, Nerich V, Jais JP, Salles G, Henry-Amar M, Mounier N.

Bull Cancer. 2017 Mar;104(3):221-231. doi: 10.1016/j.bulcan.2017.01.007. Epub 2017 Feb 15. French.

PMID:
28214006
28.

Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin.

Dobay MP, Lemonnier F, Missiaglia E, Bastard C, Vallois D, Jais JP, Scourzic L, Dupuy A, Fataccioli V, Pujals A, Parrens M, Le Bras F, Rousset T, Picquenot JM, Martin N, Haioun C, Delarue R, Bernard OA, Delorenzi M, de Leval L, Gaulard P.

Haematologica. 2017 Apr;102(4):e148-e151. doi: 10.3324/haematol.2016.158428. Epub 2017 Jan 12. No abstract available.

29.

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.

Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C, Schiano JM, Coiffier B, Corront B, Farhat H, Fruchart C, Ghesquieres H, Macro M, Tilly H, Choufi B, Delarue R, Fitoussi O, Gabarre J, Haioun C, Jardin F.

Lancet Haematol. 2017 Jan;4(1):e46-e55. doi: 10.1016/S2352-3026(16)30171-5.

PMID:
28041583
30.

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.

Dubois S, Viailly PJ, Bohers E, Bertrand P, Ruminy P, Marchand V, Maingonnat C, Mareschal S, Picquenot JM, Penther D, Jais JP, Tesson B, Peyrouze P, Figeac M, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Fabiani B, Delarue R, Peyrade F, André M, Ketterer N, Leroy K, Salles G, Molina TJ, Tilly H, Jardin F.

Clin Cancer Res. 2017 May 1;23(9):2232-2244. doi: 10.1158/1078-0432.CCR-16-1922. Epub 2016 Dec 6.

31.

Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.

Wanquet A, Birsen R, Bonnet C, Boubaya M, Choquet S, Dupuis J, Lepretre S, Re D, Fahri J, Michallet AS, Ysebaert L, Lemal R, Lamy T, Delarue R, Troussard X, Cymbalista F, Levy V, Dietrich PY, Leblond V, Aurran-Schleinitz T.

Br J Haematol. 2017 Jan;176(1):37-49. doi: 10.1111/bjh.14387. Epub 2016 Nov 11.

PMID:
27858991
32.

A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts.

Ghesquières H, Larrabee BR, Casasnovas O, Maurer MJ, McKay JD, Ansell SM, Montgomery D, Asmann YW, Farrell K, Verney A, Slager SL, Allmer C, Perrot A, Delarue R, Habermann TM, Dupuis J, Link BK, Canioni D, Dogan A, Cozen W, Jarrett RF, Cerhan JR, Salles G.

Br J Haematol. 2018 Jan;180(2):286-290. doi: 10.1111/bjh.14306. Epub 2016 Sep 9. No abstract available.

33.

Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.

Saillard C, Guermouche H, Derrieux C, Bruneau J, Frenzel L, Couronne L, Asnafi V, Macintyre E, Trinquand A, Lhermitte L, Molina T, Suarez F, Lemonnier F, Kosmider O, Delarue R, Hermine O, Cheminant M.

Hematol Oncol. 2017 Dec;35(4):864-868. doi: 10.1002/hon.2319. Epub 2016 Jun 29.

PMID:
27353473
34.

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network.

Lancet. 2016 Aug 6;388(10044):565-75. doi: 10.1016/S0140-6736(16)00739-X. Epub 2016 Jun 14.

PMID:
27313086
35.

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.

Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S, Dubois S, Sola B, Ochmann M, Lemonnier F, Viailly PJ, Bertrand P, Maingonnat C, Traverse-Glehen A, Gaulard P, Damotte D, Delarue R, Haioun C, Argueta C, Landesman Y, Salles G, Jais JP, Figeac M, Copie-Bergman C, Molina TJ, Picquenot JM, Cornic M, Fest T, Milpied N, Lemasle E, Stamatoullas A, Moeller P, Dyer MJ, Sundstrom C, Bastard C, Tilly H, Leroy K.

Am J Hematol. 2016 Sep;91(9):923-30. doi: 10.1002/ajh.24451. Epub 2016 Jul 4.

36.

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.

Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, Brice P, Soubeyran P, Gomes Da Silva M, Mounier C, Offner F, Dupuis J, Caballero D, Canioni D, Paula M, Delarue R, Zachee P, Seymour J, Salles G, Tilly H.

J Clin Oncol. 2016 Aug 1;34(22):2575-82. doi: 10.1200/JCO.2015.65.7163. Epub 2016 Jun 13. Erratum in: J Clin Oncol. 2016 Sep 10;34(26):3230.

PMID:
27298402
37.

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.

Ghesquières H, Larrabee BR, Haioun C, Link BK, Verney A, Slager SL, Ketterer N, Ansell SM, Delarue R, Maurer MJ, Fitoussi O, Habermann TM, Peyrade F, Dogan A, Molina TJ, Novak AJ, Tilly H, Cerhan JR, Salles G.

Hematol Oncol. 2017 Dec;35(4):447-455. doi: 10.1002/hon.2305. Epub 2016 Jun 10.

38.

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.

Pilorge S, Harel S, Ribrag V, Larousserie F, Willems L, Franchi P, Legoff M, Biau D, Anract P, Roux C, Blanc-Autran E, Delarue R, Gisselbrecht C, Ketterer N, Recher C, Bonnet C, Peyrade F, Haioun C, Tilly H, Salles G, Brice P, Bouscary D, Deau B, Tamburini J.

Leuk Lymphoma. 2016 Dec;57(12):2820-2826. Epub 2016 Apr 27. Erratum in: Leuk Lymphoma. 2017 Feb;58(2):507-508.

39.

Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.

Dubois S, Viailly PJ, Mareschal S, Bohers E, Bertrand P, Ruminy P, Maingonnat C, Jais JP, Peyrouze P, Figeac M, Molina TJ, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Brière J, Petrella T, Canioni D, Fabiani B, Coiffier B, Delarue R, Peyrade F, Bosly A, André M, Ketterer N, Salles G, Tilly H, Leroy K, Jardin F.

Clin Cancer Res. 2016 Jun 15;22(12):2919-28. doi: 10.1158/1078-0432.CCR-15-2305. Epub 2016 Jan 27.

40.

Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).

Cottereau AS, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M, Charrier N, Bertrand S, Delarue R, Bonnet C, Hustinx R, Gaulard P, de Leval L, Vera P, Itti E, Mounier N, Haioun C, Tilly H, Meignan M.

Ann Oncol. 2016 Apr;27(4):719-24. doi: 10.1093/annonc/mdw011. Epub 2016 Jan 19.

41.

Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.

Lamarque M, Bossard C, Contejean A, Brice P, Parrens M, Le Gouill S, Brière J, Bouabdallah R, Canioni D, Tilly H, Bouchindhomme B, Bachy E, Delarue R, Haioun C, Gaulard P.

Haematologica. 2016 Mar;101(3):e103-6. doi: 10.3324/haematol.2015.135400. Epub 2015 Dec 24. No abstract available.

42.

Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.

Cheminant M, Derrieux C, Touzart A, Schmit S, Grenier A, Trinquand A, Delfau-Larue MH, Lhermitte L, Thieblemont C, Ribrag V, Cheze S, Sanhes L, Jardin F, Lefrère F, Delarue R, Hoster E, Dreyling M, Asnafi V, Hermine O, Macintyre E.

Haematologica. 2016 Mar;101(3):336-45. doi: 10.3324/haematol.2015.134957. Epub 2015 Dec 24.

43.

[What's new in ... hematology].

Delarue R.

Rev Prat. 2015 Sep;65(7):941-4. French. No abstract available.

PMID:
26619731
44.

Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.

Lazarovici J, Dartigues P, Brice P, Obéric L, Gaillard I, Hunault-Berger M, Broussais-Guillaumot F, Gyan E, Bologna S, Nicolas-Virelizier E, Touati M, Casasnovas O, Delarue R, Orsini-Piocelle F, Stamatoullas A, Gabarre J, Fornecker LM, Gastinne T, Peyrade F, Roland V, Bachy E, André M, Mounier N, Fermé C.

Haematologica. 2015 Dec;100(12):1579-86. doi: 10.3324/haematol.2015.133025. Epub 2015 Oct 1.

45.

MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.

Copie-Bergman C, Cuillière-Dartigues P, Baia M, Briere J, Delarue R, Canioni D, Salles G, Parrens M, Belhadj K, Fabiani B, Recher C, Petrella T, Ketterer N, Peyrade F, Haioun C, Nagel I, Siebert R, Jardin F, Leroy K, Jais JP, Tilly H, Molina TJ, Gaulard P.

Blood. 2015 Nov 26;126(22):2466-74. doi: 10.1182/blood-2015-05-647602. Epub 2015 Sep 15.

PMID:
26373676
46.

Prognosis and outcome of stem cell transplantation for mantle cell lymphoma.

Cheminant M, Robinson S, Ribrag V, Le Gouill S, Suarez F, Delarue R, Hermine O.

Expert Rev Hematol. 2015 Aug;8(4):493-504. doi: 10.1586/17474086.2015.1047759. Epub 2015 Jun 19. Review.

PMID:
26091558
47.

Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets.

de Leval L, Parrens M, Le Bras F, Jais JP, Fataccioli V, Martin A, Lamant L, Delarue R, Berger F, Arbion F, Bossard C, Copin MC, Canioni D, Charlotte F, Damaj G, Dartigues P, Fabiani B, Ledoux-Pilon A, Montagne K, Molina T, Patey M, Tas P, Peoch M, Petit B, Petrella T, Picquenot JM, Rousset T, Rousselet MC, Soubeyran I, Thiebault S, Tournilhac O, Xerri L, Gisselbrecht C, Haioun C, Delsol G, Gaulard P.

Haematologica. 2015 Sep;100(9):e361-4. doi: 10.3324/haematol.2015.126300. Epub 2015 Jun 4. No abstract available.

48.

Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma.

Jordheim LP, Ribrag V, Ghesquieres H, Pallardy S, Delarue R, Tilly H, Haioun C, Jardin F, Demangel D, Salles GA, Dumontet C.

Haematologica. 2015 May;100(5):e204-6. doi: 10.3324/haematol.2014.120113. Epub 2015 Jan 30. No abstract available.

49.

Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma.

Cheminant M, Bruneau J, Kosmider O, Lefrere F, Delarue R, Gaulard P, Radford I, Derrieux C, Hermine O, Lemonnier F.

Br J Haematol. 2015 Mar;168(6):913-6. doi: 10.1111/bjh.13170. Epub 2014 Oct 14. No abstract available.

PMID:
25312805
50.

Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.

Bossard C, Dobay MP, Parrens M, Lamant L, Missiaglia E, Haioun C, Martin A, Fabiani B, Delarue R, Tournilhac O, Delorenzi M, Gaulard P, de Leval L.

Blood. 2014 Nov 6;124(19):2983-6. doi: 10.1182/blood-2014-07-584953. Epub 2014 Sep 15.

PMID:
25224410

Supplemental Content

Loading ...
Support Center